会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 60. 发明公开
    • 신규한 이종고리화합물 및 이의 용도
    • 新型杂环化合物及其用途
    • KR1020140095388A
    • 2014-08-01
    • KR1020130008307
    • 2013-01-24
    • 한국생명공학연구원
    • 노문철송양헌이승웅박찬선오현미
    • C07D513/04A61K31/429A61P29/00A61P37/00
    • The present invention relates to a novel compound represented by chemical formula 1 below, or a pharmaceutically acceptable salt thereof; to a preparation method of the novel compound; and to a pharmaceutical composition comprising the novel compound or a pharmaceutically acceptable salt thereof as an active ingredient to prevent or treat IL-6-mediated diseases, and a health functional food comprising the novel compound or a pharmaceutically acceptable salt thereof as an active ingredient to prevent or alleviate IL-6-mediated diseases. Novel sulfur-linked heterocyclic compounds in the present invention are small molecules. Therefore, when the heterocyclic compounds are used for a therapeutic agent, the heterocyclic compounds do not cause immune response, and simultaneously inhibits the transcription activity and phosphorylation of STAT3 which is an inflammation-related transcription factor activated by IL-6. Accordingly, the heterocyclic compounds can widely be used for the development of a preventive or therapeutic agent for IL-6-mediated diseases.
    • 本发明涉及由下述化学式1表示的新化合物或其药学上可接受的盐; 涉及新化合物的制备方法; 以及包含所述新化合物或其药学上可接受的盐作为预防或治疗IL-6介导的疾病的活性成分的药物组合物,以及包含所述新化合物或其药学上可接受的盐作为活性成分的保健功能性食品, 预防或减轻IL-6介导的疾病。 本发明中的新型硫键杂环化合物是小分子。 因此,当杂环化合物用于治疗剂时,杂环化合物不引起免疫应答,同时抑制作为IL-6激活的炎症相关转录因子的STAT3的转录活性和磷酸化。 因此,杂环化合物可广泛用于开发IL-6介导的疾病的预防或治疗剂。